pioglitazone has been researched along with Congenital Myotonic Dystrophy in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the effects of pioglitazone in overweight patients with myotonic dystrophy and type 2 diabetes mellitus have not been established." | 7.75 | Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. ( Abe, H; Funayama, T; Hirose, T; Ikeda, F; Kaga, H; Kanazawa, A; Kawamori, R; Kudo, K; Mita, T; Tokoro, M; Watada, H, 2009) |
| "We report beneficial effects of pioglitazone on insulin resistance in diabetes mellitus accompanied with myotonic dystrophy (DM1)." | 7.73 | [Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone]. ( Isobe, T; Kawai, M; Ogata, K; Ogawa, M; Oya, Y; Shirafuji, T; Yamamoto, T, 2005) |
| "Pioglitazone was effective in improving hyperinsulinemia and reactive hypoglycemia in nondiabetic DM1." | 5.35 | [Successful treatment of recurrent hypoglycemia by pioglitazone in a patient with myotonic dystrophy]. ( Furusawa, Y; Murata, M; Nonaka, I; Oya, Y; Yamamoto, T, 2009) |
| " However, the effects of pioglitazone in overweight patients with myotonic dystrophy and type 2 diabetes mellitus have not been established." | 3.75 | Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. ( Abe, H; Funayama, T; Hirose, T; Ikeda, F; Kaga, H; Kanazawa, A; Kawamori, R; Kudo, K; Mita, T; Tokoro, M; Watada, H, 2009) |
| "We report beneficial effects of pioglitazone on insulin resistance in diabetes mellitus accompanied with myotonic dystrophy (DM1)." | 3.73 | [Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone]. ( Isobe, T; Kawai, M; Ogata, K; Ogawa, M; Oya, Y; Shirafuji, T; Yamamoto, T, 2005) |
| "Pioglitazone was effective in improving hyperinsulinemia and reactive hypoglycemia in nondiabetic DM1." | 1.35 | [Successful treatment of recurrent hypoglycemia by pioglitazone in a patient with myotonic dystrophy]. ( Furusawa, Y; Murata, M; Nonaka, I; Oya, Y; Yamamoto, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H | 1 |
| Mita, T | 1 |
| Kudo, K | 1 |
| Funayama, T | 1 |
| Tokoro, M | 1 |
| Kaga, H | 1 |
| Ikeda, F | 1 |
| Kanazawa, A | 1 |
| Hirose, T | 1 |
| Kawamori, R | 1 |
| Watada, H | 1 |
| Yamamoto, T | 2 |
| Oya, Y | 2 |
| Furusawa, Y | 1 |
| Nonaka, I | 1 |
| Murata, M | 1 |
| Isobe, T | 1 |
| Shirafuji, T | 1 |
| Ogata, K | 1 |
| Ogawa, M | 1 |
| Kawai, M | 1 |
3 other studies available for pioglitazone and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Myotonic Dystrophy; O | 2009 |
[Successful treatment of recurrent hypoglycemia by pioglitazone in a patient with myotonic dystrophy].
Topics: Adult; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Myotonic Dystrophy; Pioglitazone; Thiazoli | 2009 |
[Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mid | 2005 |